The present invention relates to the treatment of subjects infected with HCV which have been identified as likely responders to HCV therapy with a miR-122 inhibitor. The invention also provides for prognostic methods for determining the suitability of treatment of hepatitis C infection with an anti-HCV agent such as a miR-122 inhibitor.
展开▼